Zai Lab (NASDAQ:ZLAB) Posts Earnings Results, Beats Estimates By $0.18 EPS

Zai Lab (NASDAQ:ZLAB) announced its quarterly earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18, Zacks reports. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. The business had revenue of $108.21 million during the quarter, compared to the consensus estimate of $107.90 million.

Here are the key takeaways from Zai Lab’s conference call:

• Zoci’s early first-line small cell lung cancer data were encouraging: In 33 evaluable patients, zoci plus atezolizumab produced an 81.8% confirmed response rate and estimated six-month progression-free survival of 81.9%, with grade 3 or higher zoci-related adverse events in 9.1%. The results are from a small early-stage study; Zai Lab plans a global phase III trial and is targeting a potential U.S. BLA submission in 2027.
• Zai Lab expects three registrational studies to be underway by year-end and anticipates two registrational readouts in 2027. For zoci, a potential accelerated-approval filing in second-line or later small cell lung cancer depends on the DLLEVATE interim analysis, while an epNEC filing would depend on forthcoming data and durability follow-up.
• China product revenue increased 2% sequentially, and the commercial business remained profitable. Management expects a return to year-over-year product revenue growth in 2027, citing potential NRDL access expansion and demand across priority brands; that outlook remains a company forecast.
• Zai Lab reported $659.7 million in cash at quarter-end and raised approximately $250 million in October. Management said stable R&D and SG&A expenses, operational efficiencies, and the financing support investment in its global pipeline.
• The company plans to present the first human data for its internally developed atopic dermatitis candidate ZL-1503 next week, with patient efficacy data and an IV-to-subcutaneous bridging study expected in 2027. Zai Lab is also advancing additional oncology and immunology assets, though these programs remain at earlier development stages.

Zai Lab Price Performance

Zai Lab stock opened at $22.60 on Friday. The stock has a fifty day moving average of $24.64 and a two-hundred day moving average of $21.02. Zai Lab has a fifty-two week low of $15.96 and a fifty-two week high of $27.50.

Insiders Place Their Bets

In other news, Director William Lis sold 8,506 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total value of $212,650.00. Following the completion of the transaction, the director owned 41,931 shares of the company’s stock, valued at $1,048,275. The trade was a 16.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 9,385 shares of company stock valued at $235,145. Insiders own 4.88% of the company’s stock.

Zai Lab News Roundup

Here are the key news stories impacting Zai Lab this week:

• Positive Sentiment: Zai Lab reported a Q3 loss of $0.41 per ADS, better than analysts’ estimates of roughly $0.58–$0.59, and revenue of $108.21 million, slightly above the $107.90 million consensus. The earnings surprise is a near-term positive, though the loss shows the company is not yet profitable. Earnings results
• Positive Sentiment: The company highlighted pipeline progress, with a report pointing to a potential first U.S. drug filing ahead. A successful filing could be an important step toward expanding Zai Lab’s internally developed medicines, although timing and approval remain uncertain. Pipeline update
• Negative Sentiment: Despite beating quarterly estimates, coverage said revenue declined year over year, and Zai Lab continues to report losses. That may temper the impact of the estimate beat and keep attention on whether product growth and pipeline advances can improve the financial trend. Quarterly performance coverage

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ZLAB shares. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Wall Street Zen raised shares of Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a report on Tuesday, October 27th. Finally, Citigroup raised their target price on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.25.

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.